UnitedHealthcare Opzelura Prior Auth Policy Update

Coverage Criteria

Initial Therapy (Atopic Dermatitis)

Initial authorization for mild to moderate atopic dermatitis — Covered when ALL of the following are met

Atopic dermatitis diagnosis: (1) Diagnosis of mild to moderate atopic dermatitis

Prior topical therapy trial: (2) History of failure, contraindication, or intolerance to ONE of the following topical therapy options

For moderate atopic dermatitis require a topical corticosteroid of at least medium- to high-potency (e.g., mometasone furoate, fluocinonide); for mild disease a topical corticosteroid of any potency (e.g., desonide, hydrocortisone). Alternatives include a topical calcineurin inhibitor (e.g., pimecrolimus, tacrolimus) or crisaborole (Eucrisa)

Current Opzelura exposure via samples: (3) Patient has not been established on therapy solely via a manufacturer free sample or IncyteCARES assistance to establish current user status

Patients established on therapy via manufacturer samples or assistance must meet initial authorization criteria as new users

No contraindicated concomitant therapies: (4) Patient is not receiving Opzelura in combination with another biologic medication or systemic JAK inhibitor, nor with a potent immunosuppressant (e.g., azathioprine, cyclosporine)

Examples of biologics/JAK inhibitors listed in policy (e.g., dupilumab, omalizumab, rituximab, infliximab, ruxolitinib [systemic], tofacitinib, upadacitinib)

Initial Therapy (Nonsegmental Vitiligo)

Initial authorization for nonsegmental vitiligo — Covered when ALL of the following are met

Vitiligo diagnosis: (1) Diagnosis of nonsegmental vitiligo

Other causes of depigmentation must be ruled out (e.g., nevus depigmentosus, pityriasis alba, idiopathic guttate hypomelanosis, tinea versicolor, halo nevus, piebaldism, progressive macular hypomelanosis, lichen sclerosus, chemical or drug-induced leukoderma, hypopigmented mycosis fungoides)

Extent limit: (2) Affected areas do not exceed 10% body surface area≤ 10% BSA

Prior vitiligo therapy trial: (3) History of failure, contraindication, or intolerance to prior nonsegmental vitiligo topical treatments (e.g., topical corticosteroids, topical calcineurin inhibitors)

No contraindicated concomitant therapies:

Reauthorization (Both Indications)

Reauthorization — Covered when ALL of the following are met

Clinical response: (1) Documentation of positive clinical response to therapy

Required for reauthorization

No contraindicated concomitant therapies: (2) Patient is not receiving Opzelura in combination with another biologic medication or systemic JAK inhibitor, nor with a potent immunosuppressant (e.g., azathioprine, cyclosporine)

Opzelura must not be used concomitantly with systemic immunomodulatory therapies that could increase risk or confound assessment of response. Specifically, coverage is precluded when the patient is receiving a therapeutic biologic (e.g., dupilumab, omalizumab, rituximab, etanercept, infliximab), another JAK inhibitor (e.g., oral ruxolitinib/Jakafi, tofacitinib/Xeljanz, upadacitinib/Rinvoq), or a potent immunosuppressant (e.g., azathioprine, cyclosporine).

Patients who were established on therapy solely through manufacturer-provided samples or IncyteCARES assistance are considered new users for authorization purposes and must meet initial authorization requirements rather than be continued automatically. Authorization will not be granted where combination use with the agents listed above is documented.

For initial authorization, documentation of prior topical therapy failure, contraindication, or intolerance is required. This means either a history of inadequate response or inability to use appropriate topical treatments — for moderate atopic dermatitis this includes a trial of a medium- to high-potency topical corticosteroid (e.g., mometasone, fluocinonide); for mild atopic dermatitis any-potency topical corticosteroid is acceptable. Acceptable alternatives include a topical calcineurin inhibitor (e.g., pimecrolimus, tacrolimus) or crisaborole (Eucrisa).

Use of Opzelura without documented trials or a documented contraindication/intolerance to these topical options may be considered not medically necessary. The requirement for prior topical therapy is linked to the labeled indication and disease severity: providers should verify and document the severity (mild versus moderate) and the specific topical agents tried before requesting coverage.

Patients who were established on therapy solely via a manufacturer sample or program assistance must still meet the prior therapy requirement and other initial-authorization criteria as if they were new to treatment.

Initial Therapy

Initial Therapy (Drug-specific)

Initial authorization — drug-specific requirements

Indicated diagnosis: (1) Diagnosis of the indicated condition (mild to moderate atopic dermatitis or nonsegmental vitiligo)

Prior topical therapy failure (drug-specific): (2) History of failure, contraindication, or intolerance to specified topical therapies

For moderate atopic dermatitis require medium- to high-potency topical corticosteroid; for mild disease any potency; alternatives include topical calcineurin inhibitor or Eucrisa; for vitiligo prior topical corticosteroids or topical calcineurin inhibitors

Vitiligo extent limit (drug-specific): (3) For vitiligo indication, affected areas must not exceed 10% BSA≤ 10% BSA

Step Therapy Requirements

Step	Required trial prior to Opzelura
1
Trial of a topical corticosteroid (potency by disease severity): for moderate atopic dermatitis a medium- to high-potency topical corticosteroid (e.g., mometasone furoate, fluocinolone acetonide, fluocinonide); for mild atopic dermatitis any potency (e.g., desonide, hydrocortisone)
OR trial of a topical calcineurin inhibitor (e.g., pimecrolimus, tacrolimus)
OR trial of crisaborole (Eucrisa)

Continuation / Reauthorization Criteria

Continuation Therapy

Reauthorization rules — continuation requirements

Positive clinical response documented: (1) Documentation of positive clinical response to therapy is required for continuation/reauthorization

No prohibited concomitant drugs: (2) Patient must not be receiving Opzelura in combination with another biologic medication or systemic JAK inhibitor, nor with a potent immunosuppressant (e.g., azathioprine, cyclosporine)

Coding / Definitions

Affected body surface area (vitiligo)

Vitiligo affected area limitAffected areas not to exceed 10% body surface area (≤ 10% BSA)

ContextApplies to nonsegmental vitiligo initial authorization criteria

Authorization durationAuthorization will be issued for 12 months when criteria met

Nonsegmental vitiligo — definition

SubtypeNonsegmental vitiligo (the vitiligo subtype indicated for topical ruxolitinib)

Extent requirementAffected areas must not exceed 10% body surface area (≤ 10% BSA)

Exclusion of other causes

Provider Actions & Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for both initial authorization and reauthorization of Opzelura. Approvals are issued for up to 12 months when all applicable criteria are met.

Authorization duration: up to 12 months when criteria met

Step Therapy

Topical Therapy Trial Requirement

Initial therapy requires documentation of failure, contraindication, or intolerance to specified topical therapies before Opzelura will be approved. For atopic dermatitis this includes: a trial of an appropriate topical corticosteroid (for moderate disease: medium- to high‑potency; for mild disease: any potency) and one of the following: a topical calcineurin inhibitor (e.g., Elidel, Protopic) or crisaborole (Eucrisa). For nonsegmental vitiligo, prior topical therapies (topical corticosteroids, topical calcineurin inhibitors) must have failed or be contraindicated/intolerated.

Atopic dermatitis — medium‑ to high‑potency topical corticosteroid for moderate disease (e.g., mometasone, fluocinonide); any potency topical corticosteroid for mild disease (e.g., desonide, hydrocortisone)

Quantity Limits

Opzelura (ruxolitinib) — supply / quantity limits

Quantity/supply limitsSupply limits may be in place for Opzelura (ruxolitinib)

Program variabilityNotwithstanding coverage criteria, approvals and supply limits may be processed via prior claim/medication history or program-specific logic

Authorization term noteWhen criteria are met, authorization is typically issued for 12 months (see coverage criteria)

Site of Care / Manufacturer Sample Guidance

Note

Manufacturer samples do not establish current user status

Patients established on therapy solely via manufacturer in‑office samples or IncyteCARES assistance are not treated as current users; such patients must meet the initial authorization criteria and documentation requirements.

Do not rely on in‑office manufacturer samples to establish current user status.
Patients who received free samples or assistance (e.g., sample cards from IncyteCARES) must be submitted as new starts and meet initial criteria.

Background

Opzelura (ruxolitinib) is a topical Janus kinase (JAK) inhibitor labeled for short‑term and noncontinuous chronic treatment of mild to moderate atopic dermatitis in non‑immunocompromised patients aged ≥12 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. It is also approved for topical treatment of nonsegmental vitiligo in patients aged ≥12 years.

The vitiligo indication requires that other causes of depigmentation be excluded and that affected areas do not exceed 10% body surface area (BSA). The labeling and this policy recommend against combining topical ruxolitinib with systemic JAK inhibitors, biologic therapies, or potent immunosuppressants (e.g., azathioprine, cyclosporine).

Definitions

Nonsegmental vitiligo — coverage relation

DefinitionNonsegmental vitiligo — the vitiligo subtype indicated for topical ruxolitinib and covered when other causes are excluded

Age indicationIndicated in patients 12 years of age and older (per labeling)

Relation to coverage criteriaCoverage requires affected areas ≤ 10% BSA and ruling out other causes of depigmentation; prior topical vitiligo treatments must have failed, been contraindicated, or not tolerated

Revision History

2025-03-01effective_date_changeLatest

Policy effective date updated to 2025-03-01.

2022-04-01authorization_duration_change

Initial authorization duration changed to 12 months.

2022-09-01coverage_criteria_added

OpenPayer

Opzelura (ruxolitinib) prior authorization